{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T17:18:54Z","timestamp":1789924734577,"version":"4.0.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81301024"],"award-info":[{"award-number":["81301024"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Hunan Natural Science Foundation","award":["14JJ3033"],"award-info":[{"award-number":["14JJ3033"]}]},{"name":"post doctor fund of China","award":["2014M550427"],"award-info":[{"award-number":["2014M550427"]}]},{"name":"post doctor fund of China","award":["2015T80892"],"award-info":[{"award-number":["2015T80892"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.clim.2015.12.009","type":"journal-article","created":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T13:15:36Z","timestamp":1454332536000},"page":"106-113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["MiR-15a contributes abnormal immune response in myasthenia gravis by targeting CXCL10"],"prefix":"10.1016","volume":"164","author":[{"given":"Xiao-Fang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Run-Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Chuan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu-Ming","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Hua","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue-Bei","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao-Hui","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2015.12.009_bb0005","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jaut.2013.12.011","article-title":"Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms","volume":"52","author":"Berrih-Aknin","year":"2014","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.clim.2015.12.009_bb0010","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.cytogfr.2014.11.009","article-title":"CXCR3 ligands in disease and therapy","volume":"26","author":"Van Raemdonck","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.clim.2015.12.009_bb0015","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.4049\/jimmunol.168.7.3195","article-title":"IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking","volume":"168","author":"Dufour","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2015.12.009_bb0025","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1084\/jem.177.6.1809","article-title":"Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells","volume":"177","author":"Taub","year":"1993","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.clim.2015.12.009_bb0030","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.autrev.2008.07.017","article-title":"Immunopathogenesis of HCV-related endocrine manifestations in chronic hepatitis and mixed cryoglobulinemia","volume":"8","author":"Antonelli","year":"2008","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.clim.2015.12.009_bb0035","doi-asserted-by":"crossref","first-page":"510","DOI":"10.2337\/diacare.24.3.510","article-title":"Elevated serum IP-10 levels observed in type 1 diabetes","volume":"24","author":"Shimada","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clim.2015.12.009_bb0040","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1080\/08916930802170401","article-title":"High values of alpha (CXCL10) and beta (CCL2) circulating chemokines in patients with psoriatic arthritis, in presence or absence of autoimmune thyroiditis","volume":"41","author":"Antonelli","year":"2008","journal-title":"Autoimmunity"},{"key":"10.1016\/j.clim.2015.12.009_bb0045","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/nrrheum.2011.157","article-title":"Validation of new biomarkers in systemic autoimmune diseases","volume":"7","author":"Tektonidou","year":"2011","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.clim.2015.12.009_bb0050","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1126\/science.1149460","article-title":"Switching from repression to activation: microRNAs can up-regulate translation","volume":"318","author":"Vasudevan","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.clim.2015.12.009_bb0055","doi-asserted-by":"crossref","first-page":"e1020","DOI":"10.1371\/journal.pone.0001020","article-title":"miRNA profiling of naive, effector and memory CD8 T cells","volume":"2","author":"Wu","year":"2007","journal-title":"PLoS One"},{"key":"10.1016\/j.clim.2015.12.009_bb0060","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1101\/gad.1522907","article-title":"Dynamic regulation of miRNA expression in ordered stages of cellular development","volume":"21","author":"Neilson","year":"2007","journal-title":"Genes Dev."},{"key":"10.1016\/j.clim.2015.12.009_bb0065","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1007\/s11064-014-1386-z","article-title":"Biomarker studies in multiple sclerosis: from proteins to noncoding RNAs","volume":"39","author":"Liu","year":"2014","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.clim.2015.12.009_bb0070","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/carcin\/bgs333","article-title":"miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF","volume":"34","author":"Sun","year":"2013","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.clim.2015.12.009_bb0075","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.molimm.2012.04.007","article-title":"Role of microRNA-15a in autoantibody production in interferon-augmented murine model of lupus","volume":"52","author":"Yuan","year":"2012","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.clim.2015.12.009_bb0080","doi-asserted-by":"crossref","first-page":"6669","DOI":"10.1182\/blood-2009-01-198408","article-title":"MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma","volume":"113","author":"Roccaro","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clim.2015.12.009_bb0085","article-title":"MicroRNA-15a induces cell apoptosis and inhibits metastasis by targeting BCL2L2 in non-small cell lung cancer","author":"Yang","year":"2015","journal-title":"Tumour Biol."},{"key":"10.1016\/j.clim.2015.12.009_bb0090","doi-asserted-by":"crossref","first-page":"466","DOI":"10.3109\/00207454.2012.678444","article-title":"miR-15a and 16-1 are downregulated in CD4+ T cells of multiple sclerosis relapsing patients","volume":"122","author":"Lorenzi","year":"2012","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.clim.2015.12.009_bb0095","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/ard.2005.038315","article-title":"Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus","volume":"65","author":"Lit","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2015.12.009_bb0100","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1089\/thy.2009.0179","article-title":"Serum chemokine (C-X-C motif) ligand 10 levels are elevated in patients with Graves' disease in long-term remission","volume":"20","author":"Sakai","year":"2010","journal-title":"Thyroid"},{"key":"10.1016\/j.clim.2015.12.009_bb0105","doi-asserted-by":"crossref","first-page":"5324","DOI":"10.4049\/jimmunol.174.9.5324","article-title":"Overexpression of IFN-induced protein 10 and its receptor CXCR3 in myasthenia gravis","volume":"174","author":"Feferman","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2015.12.009_bb0110","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jneuroim.2009.01.021","article-title":"Suppression of experimental autoimmune myasthenia gravis by inhibiting the signaling between IFN-gamma inducible protein 10 (IP-10) and its receptor CXCR3","volume":"209","author":"Feferman","year":"2009","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.clim.2015.12.009_bb0115","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.clim.2013.10.009","article-title":"Up-regulation of microRNA-210 induces immune dysfunction via targeting FOXP3 in CD4(+) T cells of psoriasis vulgaris","volume":"150","author":"Zhao","year":"2014","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clim.2015.12.009_bb0120","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.clim.2013.03.010","article-title":"The role of miR-155 in regulatory T cells and rheumatoid arthritis","volume":"148","author":"Spoerl","year":"2013","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clim.2015.12.009_bb0125","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.clim.2013.01.011","article-title":"Signature MicroRNA expression patterns identified in humans with 22q11.2 deletion\/DiGeorge syndrome","volume":"147","author":"de la Morena","year":"2013","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clim.2015.12.009_bb0130","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.clim.2012.04.002","article-title":"Altered microRNA expression in B lymphocytes in multiple sclerosis: towards a better understanding of treatment effects","volume":"144","author":"Sievers","year":"2012","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clim.2015.12.009_bb0135","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/cdd.2009.69","article-title":"miR-15a and miR-16-1 in cancer: discovery, function and future perspectives","volume":"17","author":"Aqeilan","year":"2010","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.clim.2015.12.009_bb0140","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.jaci.2013.06.041","article-title":"Lower levels of hsa-mir-15a, which decreases VEGFA, in the CD4+ T cells of pediatric patients with asthma","volume":"132","author":"Nakano","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2015.12.009_bb0145","doi-asserted-by":"crossref","first-page":"4558","DOI":"10.4049\/jimmunol.1401372","article-title":"miR-15a\/16 regulates macrophage phagocytosis after bacterial infection","volume":"193","author":"Moon","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2015.12.009_bb0150","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s10875-012-9834-5","article-title":"MiR-320a is downregulated in patients with myasthenia gravis and modulates inflammatory cytokines production by targeting mitogen-activated protein kinase 1","volume":"33","author":"Cheng","year":"2013","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.clim.2015.12.009_bb0155","doi-asserted-by":"crossref","first-page":"e91927","DOI":"10.1371\/journal.pone.0091927","article-title":"Analysis of serum miRNA profiles of myasthenia gravis patients","volume":"9","author":"Nogales-Gadea","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.clim.2015.12.009_bb0160","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.12659\/MSM.893458","article-title":"miR-15b is downregulated in myasthenia gravis patients and directly regulates the expression of interleukin-15 (IL-15) in experimental myasthenia gravis mice","volume":"21","author":"Shi","year":"2015","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.clim.2015.12.009_bb0165","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/leu.2008.370","article-title":"Glucocorticoid-regulated microRNAs and mirtrons in acute lymphoblastic leukemia","volume":"23","author":"Rainer","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clim.2015.12.009_bb0170","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jlb.67.1.2","article-title":"CD40-CD40 ligand","volume":"67","author":"van Kooten","year":"2000","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.clim.2015.12.009_bb0175","doi-asserted-by":"crossref","first-page":"6893","DOI":"10.4049\/jimmunol.166.11.6893","article-title":"Blockade of CD40 ligand suppresses chronic experimental myasthenia gravis by down-regulation of Th1 differentiation and up-regulation of CTLA-4","volume":"166","author":"Im","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2015.12.009_bb0180","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.4049\/jimmunol.0903111","article-title":"Activation of tolerogenic dendritic cells in the tumor draining lymph nodes by CD8+ T cells engineered to express CD40 ligand","volume":"184","author":"Higham","year":"2010","journal-title":"J. Immunol."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661615300784?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661615300784?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T01:17:02Z","timestamp":1567559822000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661615300784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":35,"alternative-id":["S1521661615300784"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2015.12.009","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MiR-15a contributes abnormal immune response in myasthenia gravis by targeting CXCL10","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2015.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}